Zhejiang Cancer Hospital
🇨🇳China
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
Phase 2
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT04061772
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma
Phase 2
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Drug: Decitabine; Oxaliplatin
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT04049344
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Adujvant CT+CRT vs Adujvant CT After D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Gastric Adenocarcinoma
- Interventions
- Radiation: Adjuvant ChemoradiotherapyDrug: Adjuvant Chemotherapy
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 408
- Registration Number
- NCT03973008
- Locations
- 🇨🇳
Jinwen Shen, Hangzhou, Zhejiang, China
A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
Early Phase 1
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Biological: SintilimabDrug: carboplatin/paclitaxelRadiation: Radiation
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03940001
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03907098
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis
Phase 2
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: Tegafur-Gimeracil-Oteracil
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT03904225
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
Phase 2
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 79
- Registration Number
- NCT03876587
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03821454
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
Not Applicable
- Conditions
- Breast CancerBreast NeoplasmsBreast Diseases
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03756090
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
Not Applicable
- Conditions
- Breast CancerBreast DiseasesNeoplasm, Breast
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03756064
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath